Clinical implication intra-tumor heterogeneity

4 important questions on Clinical implication intra-tumor heterogeneity

Where are tumors resistant agains therapy?

  • Chemotherapy
  • Differentiation therapy - Retinoic acid

Which cells of the neuroblastoma are therapy-resistant?

MES cells are resistant to chemotherapy, while ADRN cells are sensitive to it.
  • MES cells survive therapy better than ADRN
  • MES cells - resistant to Retinoic acid (can be checked with marker PRRX1 presence)

Minimal residual disease (MRD) - monitoring

measures response to therapy
  • MDR-markers are mainly expressed in ADRN cells
  • MES cells hardly express these ADRN MRD markers
  • MES cells may escape detection
  • Tumor specific DNA translocation provide alternative MRD-markers
  • Higher grades + faster learning
  • Never study anything twice
  • 100% sure, 100% understanding
Discover Study Smart

How to develop new therapies?

Combination therapy: lessons from glioma
  • Also two cell types with different epigenetic regulation
  • Combination of BM1 and EZH2 inhibition therapy cleared 100% of tumor cells in vitro and almost completely in vivo


Different drug with different marker for a specific cancer cell type line cure the tumor best! Eliminates both cell types

The question on the page originate from the summary of the following study material:

  • A unique study and practice tool
  • Never study anything twice again
  • Get the grades you hope for
  • 100% sure, 100% understanding
Remember faster, study better. Scientifically proven.
Trustpilot Logo